MX345544B - Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). - Google Patents

Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).

Info

Publication number
MX345544B
MX345544B MX2013004814A MX2013004814A MX345544B MX 345544 B MX345544 B MX 345544B MX 2013004814 A MX2013004814 A MX 2013004814A MX 2013004814 A MX2013004814 A MX 2013004814A MX 345544 B MX345544 B MX 345544B
Authority
MX
Mexico
Prior art keywords
ligands
triazole derivatives
gaba receptors
present
compounds
Prior art date
Application number
MX2013004814A
Other languages
English (en)
Other versions
MX2013004814A (es
Inventor
Thomas Andrew
Deems Gabriel Stephen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013004814A publication Critical patent/MX2013004814A/es
Publication of MX345544B publication Critical patent/MX345544B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de triazol de fórmula (I) en donde A, X, Y, u,v, R1, R2, y R3 son como se describen en la presente, así como también sales de los mismos farmacéuticamente aceptables. Los compuestos activos de la presente invención tienen afinidad y selectividad para el receptor GABA A a5. Además, la presente invención está relacionada con la manufactura de compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos.
MX2013004814A 2010-11-09 2011-11-02 Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). MX345544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190548 2010-11-09
PCT/EP2011/069192 WO2012062623A1 (en) 2010-11-09 2011-11-02 Triazole derivatives as ligands for gaba receptors

Publications (2)

Publication Number Publication Date
MX2013004814A MX2013004814A (es) 2013-06-28
MX345544B true MX345544B (es) 2017-02-03

Family

ID=44913272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004814A MX345544B (es) 2010-11-09 2011-11-02 Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).

Country Status (12)

Country Link
US (1) US8697696B2 (es)
EP (1) EP2638035B1 (es)
JP (1) JP5919291B2 (es)
KR (1) KR20130100348A (es)
CN (1) CN103189370B (es)
BR (1) BR112013011265A2 (es)
CA (1) CA2815741A1 (es)
ES (1) ES2536667T3 (es)
HK (1) HK1182101A1 (es)
MX (1) MX345544B (es)
RU (1) RU2582337C2 (es)
WO (1) WO2012062623A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876780A1 (en) * 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
WO2021191837A1 (en) 2020-03-26 2021-09-30 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators
CN115461337A (zh) 2020-05-13 2022-12-09 豪夫迈·罗氏有限公司 作为GABA A α5 PAM的新型三唑基衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229011A1 (de) * 1986-01-06 1987-07-15 Ciba-Geigy Ag Trisubstituierte Triazole
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
JP2002527519A (ja) * 1998-10-16 2002-08-27 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのピラゾロトリアジン誘導体
JP2002529468A (ja) * 1998-11-12 2002-09-10 メルク エンド カムパニー インコーポレーテッド ＧＡＢＡ−Ａα−５逆活性薬の治療性多形およびそのパモエート組成物
EP1720860A1 (en) * 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
CL2007001451A1 (es) * 2006-05-24 2008-01-11 Eli Lilly And Company Soc Organizada Bajo Las Leyes Del Estado De Indiana Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
HUE039416T2 (hu) * 2008-06-19 2018-12-28 Takeda Pharmaceuticals Co Heterociklusos vegyület és ennek alkalmazása
MX2011011273A (es) * 2009-05-05 2011-11-04 Hoffmann La Roche Derivados de isoxazol-pirazol.
EP2298296A1 (en) * 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Composition and method for treating cognitive impairments in down syndrome subjects

Also Published As

Publication number Publication date
JP5919291B2 (ja) 2016-05-18
KR20130100348A (ko) 2013-09-10
RU2013125338A (ru) 2014-12-20
MX2013004814A (es) 2013-06-28
US20120115868A1 (en) 2012-05-10
JP2013542234A (ja) 2013-11-21
EP2638035A1 (en) 2013-09-18
CA2815741A1 (en) 2012-05-18
WO2012062623A1 (en) 2012-05-18
ES2536667T3 (es) 2015-05-27
RU2582337C2 (ru) 2016-04-27
BR112013011265A2 (pt) 2016-11-01
CN103189370A (zh) 2013-07-03
US8697696B2 (en) 2014-04-15
CN103189370B (zh) 2015-07-08
HK1182101A1 (en) 2013-11-22
EP2638035B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
IN2012DN02465A (es)
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MY173448A (en) Phenyl and benzodioxinly substituted indazoles derivatives
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
MY187718A (en) Pharmaceutical formulations
MX2011011303A (es) Derivados de isoxazol.
MY183312A (en) Pharmaceutical formulation
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
WO2012140596A8 (en) Glycoside derivatives and uses thereof
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX2013005966A (es) Nuevos compuestos de benzofurano.
UA107702C2 (en) Novel benzamide derivatives
MX342824B (es) Nuevos compuestos de triazol iii.
MY156731A (en) NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES
MX2013011728A (es) Nuevos compuestos de benzofurano-piperidina.

Legal Events

Date Code Title Description
FG Grant or registration